Traditional Chinese medicine composition for preventing and treating proventriculitis of poultry as well as preparation method and application of traditional Chinese medicine composition
Through the preparation and application of traditional Chinese medicine compositions, the prevention and treatment problems of ademosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmosmo
Patent Information
- Application Number
- CN202411140798.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-20
- Publication Date
- 2024-11-22
AI Technical Summary
Poultry adenomyosis gastritis is a common and harmful disease. The existing technology is difficult to effectively prevent and treat, resulting in economic losses and health problems in the breeding industry.
A Chinese medicine composition is used to prepare a Chinese medicine composition by using guava leaves, safflower, safflower, cinnamon, squid, conch shell and EGF. , combined with pharmaceutical excipients to make oral liquid or granules, used to treat poultry ademotomic gastritis.
The traditional Chinese medicine composition effectively regulates the adenocardium, improves the curative rate, reduces breeding losses through the effects of drying dampness, clearing heat and detoxifying, dispelling cold and relieving pain, and prevents erectile dysfunction and other effects. It also has the advantages of green, safe and preventing and treating.
Smart Images

Figure BDA0005000731420000051 
Figure BDA0005000731420000061 
Figure BDA0005000731420000062
Abstract
Description
Technical Field
[0001] The invention relates to the field of veterinary medicines, and in particular to a traditional Chinese medicine composition for preventing and treating poultry adenomyotic gastritis, and a preparation method and application thereof. Background Art
[0002] Poultry adenomyotic gastritis is a disease characterized by inflammation of the glandular stomach and gizzard of poultry. With the large-scale and intensive development of poultry farming, adenomyotic gastritis has become increasingly frequent, and the disease has become a common and harmful disease. The causes of the disease are relatively complex. Poor breeding environment, viral and bacterial infections, mycotoxin-contaminated feed, and unbalanced feed nutrition may all cause adenomyotic gastritis. Adenomyotic gastritis can cause growth retardation, reduced feed conversion rate, and increased mortality in poultry, causing serious economic losses to the breeding industry. Therefore, taking effective prevention and treatment measures is of great significance to ensure the healthy development of the poultry breeding industry. Summary of the invention
[0003] In view of the problems existing in the prior art, the purpose of the present invention is to provide a Chinese medicine composition for preventing and treating poultry adenomyotic gastritis and a preparation method and application thereof.
[0004] To achieve the purpose of the invention, the technical solution adopted by the present invention is as follows:
[0005] The first aspect of the present invention provides a traditional Chinese medicine composition for preventing and treating poultry adenomyotic gastritis, which is prepared from the following raw materials in parts by weight: 15 to 30 parts of guava leaves, 15 to 30 parts of red magnolia, 10 to 20 parts of taro, 10 to 20 parts of galangal, 5 to 20 parts of cinnamomum cassia, 5 to 20 parts of willow, 5 to 10 parts of conch shells and 3 to 6 parts of EGF, wherein the EGF is epidermal growth factor. Except for EGF, the raw materials are sourced from Chinese medicinal materials or Chinese medicinal extracts equivalent to the raw drug amount of the above-mentioned Chinese medicinal materials.
[0006] According to the above-mentioned traditional Chinese medicine composition, preferably, the traditional Chinese medicine composition is made of the following raw materials in parts by weight: 30 parts of guava leaves, 20 parts of red magnolia, 10 parts of taro, 10 parts of galangal, 10 parts of cinnamomum villosum, 10 parts of salix matsudana, 10 parts of conch shell and 5 parts of EGF.
[0007] The second aspect of the present invention provides a method for preparing the Chinese medicine composition described in the first aspect, comprising the following steps:
[0008] Guava leaves, galangal and cinnamon are mixed and then subjected to alcohol extraction to obtain crude extracts of guava leaves, galangal and cinnamon; the guava leaves, galangal and cinnamon residues after alcohol extraction are mixed with red magnolia, taro, willow of matsudana and conch shell in proportion, and then a solvent is added for extraction, and the mixture is filtered to collect the filtrate; the filtrate is evenly mixed with the crude extracts of guava leaves, galangal and cinnamon, and EGF is added and mixed to obtain a traditional Chinese medicine composition.
[0009] Preferably, the filtrate and the crude extract are combined and concentrated to 1 to 2 times the weight of the drug material, and EGF is added and mixed to obtain a traditional Chinese medicine composition.
[0010] Preferably, the solvent is water or ethanol solution; the extraction method is reflux extraction, the reflux temperature of water is 95-100° C., and the reflux temperature of ethanol is 85-90° C. More preferably, the concentration of the ethanol solution is 45%-75%.
[0011] Preferably, guava leaves, kaempferia galanga and cinnamomum cassia are extracted with ethanol solution having a volume fraction of 45%-75%; the mass ratio of guava leaves, kaempferia galanga and cinnamomum cassia to the ethanol solution is 1:(10-15).
[0012] The third aspect of the present invention provides use of the Chinese medicine composition described in the first aspect in the preparation of a medicament for treating poultry adenomyotic gastritis.
[0013] The fourth aspect of the present invention provides a medicine for preventing and treating poultry adenomyotic gastritis, wherein the medicine is prepared from the Chinese medicine composition described in the first aspect and pharmaceutically acceptable excipients.
[0014] Preferably, the drug is an oral dosage form. More preferably, the drug is an oral liquid, granules or extract powder. Most preferably, the drug is an oral liquid.
[0015] Preferably, the preparation method of the drug is: guava leaves, red flower magnolia, sharp tail taro, galangal, cinnamomum cassia, willow, and conch shell are mixed in proportion, and then a solvent is added for extraction, filtered, and the filtrate is collected. The filtrate is concentrated to 1 to 2 times the weight of the drug material, and the concentration temperature is 80-90°C, EGF is added and mixed, and then pharmaceutically acceptable excipients are added to obtain the drug.
[0016] More preferably, the specific steps of the preparation method of the drug are:
[0017] The medicine is obtained by adding pharmaceutically acceptable auxiliary materials to the above-mentioned traditional Chinese medicine composition.
[0018] More preferably, the auxiliary materials include preservatives and / or surfactants / appropriate auxiliary materials in appropriate amounts.
[0019] When the dosage form is an oral liquid, the preservative is potassium sorbate, which can enhance the preservative effect; and the surfactant is sorbitan fatty acid ester.
[0020] When the dosage form is extract powder or granules, the auxiliary material is sucrose and / or dextrin.
[0021] All components in the Chinese medicine composition of the present invention can be purchased from the market. The formulation principle of the Chinese medicine composition is as follows:
[0022] Guava leaves: the leaves of the dicotyledonous medicinal plant guava, Myrtaceae; sweet and astringent, neutral in nature; contains triterpenes, quercetin, guava ellagic acid glycosides, volatile oils and tannins; has the effects of drying dampness, strengthening the spleen, clearing away heat and detoxifying.
[0023] Red-flowered Magnolia: It is the bark of the red-flowered Magnolia, a tree plant of the genus Manglietia in the Magnoliaceae family. It tastes bitter and pungent and is warm in nature. It contains phenolic and alkaloid components. It has the effects of drying dampness and strengthening the spleen, and is mainly used to treat abdominal distension and pain, indigestion, vomiting, and diarrhea.
[0024] Sharp-tailed taro: It is the rhizome of the perennial evergreen herbaceous plant Sharp-tailed taro of the Araceae family. It tastes slightly bitter and is very cold. It mainly contains fumaric acid, amino acid, arginine and calcium oxalate. It has the effects of clearing away heat and detoxifying, dispersing knots and relieving pain. To prepare the sharp-tailed taro, take the clean sharp-tailed taro and mix it with salt water or spray it evenly, simmer it thoroughly, and stir-fry it in a pot over low heat until it turns gray-green and the water vapor is dry. Add 12-15g of salt for every 1kg of sharp-tailed taro.
[0025] Kaempferia galanga: a perennial low herb of the genus Kaempferia in the ginger family, with tuberous rhizomes, solitary or connected in several pieces, aromatic and spicy; warm in nature; contains volatile oils, flavonoids, and vitamins; functions of warming the middle and removing dampness; promoting qi and aiding digestion; relieving pain; mainly used to treat abdominal cold pain; vomiting and diarrhea due to cold and dampness; chest and abdominal distension, and indigestion.
[0026] Cinnamomum cassia: It is the young fruit stalk of cinnamon, a plant of the Lauraceae family; it tastes sweet and spicy and is warm in nature; it contains volatile oils, alkaloids, saponins and tannins; it has the effects of warming the interior and dispelling cold, relieving pain and stopping hiccups; it is mainly used to treat cold pain in the stomach and abdomen, hiccups, etc.
[0027] Salix matsudana: It is the branch or bark of the Salix matsudana plant of the Salicaceae family. It tastes bitter and is cold in nature. It contains flavonoids and has the functions of clearing away heat and dampness, dispelling wind and relieving pain.
[0028] Conch shell: the shell of the Muricidae family animals such as the veined red snail and the wrinkled red snail; salty in taste and cold in nature; mainly composed of calcium carbonate and other organic substances; has the functions of relieving spasms, antacidity, and resolving phlegm and dispersing nodules; used for gastric ulcers.
[0029] EGF: EGF is an active polypeptide growth factor containing 53 amino acid residues and is a very important growth-promoting factor in animals. EGF directly binds to the EGF receptor (EGFR) on the surface of intestinal epithelial cells at the outer edge of intestinal villi to form a 2EGF, 2EGFR dimer complex, causing EGFR tyrosine autophosphorylation, transmitting the extracellular EGF signal to the cytoplasm, and then to the cell nucleus through a cascade of intracellular signal molecules, regulating cell life activities such as DNA replication, cell proliferation and differentiation. EGF can stimulate the proliferation of a variety of cells, mainly epidermal cells and endothelial cells.
[0030] Compared with the prior art, the present invention has the following positive and beneficial effects:
[0031] The prescription mechanism of the Chinese medicine composition of the present invention is as follows: guava leaves and red flower manglietia are pungent and flat in nature, and have the functions of drying dampness and strengthening the spleen, clearing away heat and detoxifying as the main medicines; taro, galangal, cinnamomum and salix matsudana are the assistant medicines, which strengthen the functions of warming the interior and dispelling cold, stopping hiccups, and promoting qi circulation, dispersing knots and relieving pain; conch shells are the adjuvants for relieving spasms and suppressing acid; EGF stimulates cell proliferation and promotes the recovery of epidermal and endothelial cells of ulcerated glandular gastritis. All the medicines are used together to play the functions of drying dampness and strengthening the spleen, clearing away heat and detoxifying, dispelling cold and stopping pain, suppressing acid and stopping hiccups, regulating the functions of glandular gastritis, thereby reversing the pathogenesis and cutting off the disease. The product is green and safe, and can be regulated and treated from multiple directions and multiple targets, so that adenomyotic gastritis can be better treated.
[0032] The Chinese medicine composition of the present invention has the functions of drying dampness and strengthening the spleen, clearing away heat and detoxifying, dispelling cold and relieving pain, reducing acid and relieving hiccups, regulating the function of adenomyotic stomach, thereby reversing the pathogenesis, and has a good preventive and therapeutic effect on poultry adenomyotic gastritis. Moreover, the efficacy test shows that the Chinese medicine composition of the present invention can improve the cure rate of diseased poultry and effectively reduce breeding losses; and it has the advantages of being green, safe, and both preventive and therapeutic, and has a good market prospect. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figure 1 Histopathological sections of heart, liver, spleen, lung and kidney of chickens in the high-dose group and blank control group. DETAILED DESCRIPTION
[0034] The present invention is further described in detail below through specific examples, but the scope of the present invention is not limited thereto.
[0035] Embodiment 1:
[0036] A drug for preventing and treating poultry adenomyotic gastritis is prepared from a Chinese medicine composition and pharmaceutically acceptable excipients. The Chinese medicine composition is prepared from the following raw materials by weight: 30 parts of guava leaves, 20 parts of red magnolia, 10 parts of taro, 10 parts of galangal, 10 parts of cinnamomum cassia, 10 parts of salix matsudana, 10 parts of conch shells and 5 parts of EGF, wherein the EGF is epidermal growth factor, and except for EGF, the raw materials are sourced from Chinese medicinal materials or Chinese medicinal extracts equivalent to the raw drug amount of the above-mentioned Chinese medicinal materials.
[0037] The preparation method of the above medicine is:
[0038] A. Using 75% ethanol solution to mix guava leaves, kaempferia galanga and cinnamomea for alcohol extraction (the mass ratio of medicinal materials to 75% ethanol solution is 1:15), extract twice, each extraction time is 1.5h, filter after alcohol extraction, and obtain ethanol extract and medicinal residue; recover ethanol in the ethanol extract to obtain guava leaves, kaempferia galanga and cinnamomea crude extract;
[0039] B. Mix the guava leaves, galangal and cinnamon residues treated in step A with red manglietia, taro, willow and conch shell in proportion, add water for extraction (the mass ratio of medicinal materials to water is 1:15), extract twice, each time for 1.5 hours, filter after the extraction is completed, and collect the filtrate; combine the crude extracts of guava leaves, galangal and cinnamon with the filtrate, concentrate the filtrate to 1 to 2 times the mass of the dosing material, add EGF and mix well;
[0040] C. Add 0.2% potassium sorbate as a preservative and 0.2% sorbitan fatty acid ester as a surfactant to the solution prepared in step B, and mix the liquid medicines evenly to obtain an oral liquid medicine for preventing and treating poultry adenomyotic gastritis.
[0041] Embodiment 2:
[0042] A drug for preventing and treating poultry adenomyotic gastritis is prepared from a Chinese medicine composition and pharmaceutically acceptable excipients. The Chinese medicine composition is prepared from the following raw materials by weight: 15 parts of guava leaves, 15 parts of red magnolia, 15 parts of taro, 5 parts of galangal, 5 parts of cinnamomum cassia, 5 parts of salix matsudana, 5 parts of conch shells and 3 parts of EGF, wherein the EGF is epidermal growth factor, and except for EGF, the raw materials are sourced from Chinese medicinal materials or Chinese medicinal extracts equivalent to the raw drug amount of the above-mentioned Chinese medicinal materials.
[0043] The preparation method of the above medicine is the same as that of Example 1.
[0044] Comparative Example 1:
[0045] A drug for preventing and treating poultry adenomyotic gastritis is prepared from a Chinese medicine composition and pharmaceutically acceptable excipients. The Chinese medicine composition is prepared from the following raw materials by weight: 10 parts of conch shell and 5 parts of EGF, wherein the EGF is epidermal growth factor, and the raw materials other than EGF are sourced from Chinese medicinal materials or Chinese medicinal extracts equivalent to the raw drug amount of the above-mentioned Chinese medicinal materials.
[0046] The preparation method of the above medicine is the same as that of Example 1.
[0047] Comparative Example 2:
[0048] A medicine for preventing and treating poultry adenomyotic gastritis is prepared from a Chinese medicine composition and pharmaceutically acceptable excipients. The Chinese medicine composition is prepared from the following raw materials by weight: 30 parts of guava leaves and 25 parts of red magnolia, and the raw materials are sourced from Chinese medicinal materials.
[0049] The preparation method of the above medicine is the same as that of Example 1.
[0050] Comparative Example 3:
[0051] A medicine for preventing and treating poultry adenomyotic gastritis is prepared from a Chinese medicine composition and pharmaceutically acceptable excipients. The Chinese medicine composition is prepared from the following raw materials by weight: 10 parts of Colocasia esculenta, 10 parts of Kaempferia galanga, 10 parts of Cinnamomum cassiae and 10 parts of Salix matsudana. The raw materials are derived from Chinese medicinal materials.
[0052] The preparation method of the above medicine is the same as that of Example 1.
[0053] Amoxicillin group:
[0054] A medicine for preventing and treating poultry adenomyotic gastritis, which is 30% amoxicillin soluble powder and is suitable for chicken adenomyotic gastritis caused by bacterial infection. The medicine achieves a bactericidal effect by inhibiting bacterial cell wall synthesis.
[0055] 1. Experimental study on the efficacy of the present invention in preventing and treating poultry adenomyotic gastritis
[0056] In order to verify the efficacy of the drug for preventing and treating poultry adenomyotic gastritis of the present invention, the drug prepared in Examples 1 and 2 of the present invention was used as an example to conduct efficacy verification test. At the same time, in order to compare with the drug for preventing and treating poultry adenomyotic gastritis of the present invention, the present invention also sets up the following comparative test, namely, comparative examples 1 to 3 and amoxicillin group; the drugs in comparative examples 1 to 3 are basically the same as those in Example 1 of the present invention, except that the raw materials used in the Chinese medicine composition in the formula are different. The raw materials used in the Chinese medicine composition in comparative examples 1 to 3 are specifically shown in Table 1. The test drug used in the amoxicillin group is amoxicillin soluble powder produced by a certain enterprise, specification: 30%, batch number: 902405028, production date: 2024.05.24.
[0057] Table 1 API used in each group of the experiment
[0058]
[0059] 1. Test subjects
[0060] 240 9-day-old double-A broilers were purchased from a breeding company in Weishi County and adaptively raised for 3 days. All experimental broilers were fed broiler compound feed and had free access to food and water.
[0061] 2. Preparation of Chicken Glandular Gastritis Model
[0062] According to the modeling method verified in the preliminary experiment, the weight of each chicken was weighed before administration every day, and the administration was carried out at a fixed time. 1 mL of aflatoxin B1 (80 μg / kg) was gavage, and 1 mL of lipopolysaccharide 160 μg / kg was injected into the pectoral muscle. After continuous administration for 5 days, the autopsy revealed that the glandular stomach was edematous, the papilla was not obvious, and the muscular stomach had varying degrees of erosion, which determined that poultry adenomyotic gastritis had occurred.
[0063] 3. Experimental drugs
[0064] The test drugs are the drugs prepared in Examples 1 and 2 of the present invention, Comparative Examples 1 to 3, and an amoxicillin group.
[0065] 4. Trial Grouping and Medication
[0066] A total of 240 broilers were randomly divided into 8 groups (experimental group 1 to experimental group 8), with 30 broilers in each group.
[0067] In the morning, the aflatoxin B1 (80 μg / kg) was gavaged with 1 mL of aflatoxin B1 to the test group 6, and 1 mL of lipopolysaccharide 160 μg / kg was injected into the pectoral muscle. In the afternoon, the drugs used were respectively Example 1 to Example 2, Comparative Example 1 to Comparative Example 3, and amoxicillin group. The medication method of the test group 1 to the test group 5 was: oral administration, 0.20 ml per kg body weight, for 5 consecutive days. The medication method of the test group 6 was: oral administration, 100 mg per kg body weight, for 5 consecutive days.
[0068] Experimental group 7 was the model group. In the morning, 1 mL of aflatoxin B1 (80 μg / kg) was gavaged and 1 mL of lipopolysaccharide (160 μg / kg) was injected into the pectoral muscle. No drug treatment was used, and the mice were only given the same drinking water and feed.
[0069] The experimental group 8 was the blank group, which was only given the same drinking water and feed.
[0070] 5. Clinical efficacy observation and efficacy evaluation criteria
[0071] 5.1 Observation time
[0072] Clinical symptoms were observed daily; animals died during the experiment or were autopsied at the end of the experiment.
[0073] 5.2 Detection indicators
[0074] Gastric acid index: pH value;
[0075] Clinical manifestations and production performance indicators: average daily weight gain;
[0076] Immune indicators: bursa of Fabricius index; morphological indicators: glandular stomach and gizzard.
[0077] 5.3 Scoring criteria for adenomyosis
[0078] Traditional Chinese veterinary symptom classification standards: According to the characteristics of the disease, the symptoms are graded and quantified. The classification and quantification standards are shown in Table 2.
[0079] Table 2 Grading criteria for adenomyosis gastritis
[0080]
[0081] 5.4 Efficacy evaluation criteria
[0082] Cure: During the trial, after taking the medicine, the relevant clinical symptoms disappear and there is no recurrence, and the total symptom score does not exceed 2 points, which is considered cured.
[0083] Effective: During the trial, after medication, the total symptom score does not exceed 6 points at the end of the trial and no single score is 6 points, which is effective.
[0084] Invalidity: During the trial, after medication, if the total score exceeds 6 points or the single item score is 6 points at the end of the trial, it will be considered invalid.
[0085] Cure rate = number of cured animals / number of animals in a group × 100%.
[0086] Effective rate = (number of cured animals + number of effective animals) / number of animals in a group × 100%.
[0087] Inefficiency = number of ineffectiveness / number of animals in a group × 100%.
[0088] Among them, the symptom scoring standard for poultry adenomyotic gastritis is shown in Table 2.
[0089] 6. Test results
[0090] 6.1 pH value
[0091] Gastric acid test was conducted on broilers in each group, and the results are shown in Table 3.
[0092] Table 3 pH value test data
[0093]
[0094] As shown in Table 3, compared with the blank group, the gastric acid pH value of the model group was significantly lower than that of the blank group; the gastric acid pH of Example 1, Example 2 and Comparative Example 1 was significantly higher than that of the model group; Comparative Example 2 and Comparative Example 3 were slightly higher than those of the model group; and there was no significant difference between the amoxicillin group and the model group. This shows that Example 1, Example 2 and Comparative Example 1 have a good effect in inhibiting gastric acid, while Comparative Example 2, Comparative Example 3 and the amoxicillin group have a weaker effect in inhibiting gastric acid.
[0095] 6.2 Daily Weight Gain
[0096] The average daily weight gain of broilers in each group was tested, and the results are shown in Table 4.
[0097] Table 4 Daily average weight gain test data
[0098]
[0099] As shown in Table 4, compared with the blank group, the average daily weight gain of the chickens in the model group was significantly lower than that in the blank group; the average daily weight gain of the chickens in Example 1 and Example 2 was significantly higher than that in the model group; the average daily weight gain of the chickens in Comparative Examples 1 to Comparative Examples 3 was lower than that in the Examples; there was no significant difference in the average daily weight gain between the amoxicillin group and the model group.
[0100] 6.3 Bursal index
[0101] The bursa index of broiler chickens in each group was tested, and the results are shown in Table 5.
[0102] Table 5 Bursal index test data
[0103]
[0104] As shown in Table 5, compared with the blank group, the bursal index of the model group was significantly lower than that of the blank group; the bursal indexes of Examples 1 and 2 were significantly higher than those of the model group, among which Example 1 had a better effect; the bursal indexes of Comparative Examples 1 to 3 and the amoxicillin group were not much different from those of the model group, among which the bursal index of the amoxicillin group was the lowest, which may be because amoxicillin caused certain damage to the immune organs while inhibiting bacteria.
[0105] 6.4 Therapeutic effects of adenomyotic gastritis in poultry
[0106] SPSS20 statistical software was used for data analysis and processing. 2 The measurement data were analyzed by t test or variance analysis. The results are shown in Table 6.
[0107] Table 6 Statistics of medication and treatment effects in each experimental group
[0108] Group drug Number of experimental animals Number of cures (pcs) Cure rate (%) Effective quantity (only) Effectiveness (%) Test Group 1 Example 1 30 19 63.3% 25 83.3% Test Group 2 Example 2 30 16 53.3% 24 80.0% Experiment 3 groups Comparative Example 1 30 8 26.7% 15 50.0% Test 4 groups Comparative Example 2 30 10 33.3% 16 53.3% Test 5 groups Comparative Example 3 30 7 23.3% 12 40.0% Experiment 6 groups Amoxicillin group 30 9 30.0% 11 36.7% Experiment 7 groups Model Group 30 1 3.3% 4 13.3% Experiment 8 groups Blank group 30 / / / /
[0109] As shown in Table 6, after discontinuation of the drug, the cure rate of the test group 1 (63.3%) was the highest, followed by the test group 2 (53.3%), the test groups 3 to 6 were second, and the test group 7 was the lowest (3.3%); the effective rate of the test group 1 (83.3%) was the highest, followed by the test group 2 (80.0%), the test groups 3 to 6 were second, and the test group 7 was the lowest (13.3%). The amoxicillin group had a poor efficacy, which may be due to the fact that amoxicillin, while inhibiting bacteria, caused certain damage to the immune organs and produced drug resistance.
[0110] 2. Drug safety test of the present invention for preventing and treating poultry adenomyotic gastritis
[0111] 1. Experimental animals and drug dosage
[0112] 120 healthy chicks were evenly matched and randomly divided into 4 groups, each with 30 chicks, which were 1 times, 3 times, and 5 times the recommended dose of Example 1 and a blank control group. The chicks were given drinking water at a fixed time for 5 consecutive days and were fed with the same feed. The dosing schedule is shown in Table 7.
[0113] Table 7 Dosage regimen
[0114]
[0115] 2. Observation and testing indicators
[0116] 2.1 Clinical observation
[0117] During the test, the mental state, feeding habits and feces of the test chickens were observed, and abnormal performance was recorded. Each chicken was weighed before and after the test. If death occurred, autopsy and histopathological examination were performed.
[0118] 2.2 Weight and temperature detection
[0119] The body weight and temperature of the experimental chickens were tested before administration and on the first day after drug withdrawal, and detailed records were kept.
[0120] 2.3 Testing of routine blood indicators and blood biochemical indicators
[0121] Blood was collected and autopsied before administration and on the first day after drug withdrawal, and relevant blood routine indicators were measured. The detection indicators included the determination of red blood cell count (RBC), white blood cell count (WBC), white blood cell classification count, hemoglobin content (HGB), etc. The red blood cell and white blood cell counts were determined by the blood cell counting method, and the hemoglobin was determined by the colorimetric method.
[0122] The eight serum indexes including alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin (ALB), total protein (TP), total bilirubin (TBiL), blood glucose (GLU), uric acid (UA) and creatinine (Crea) were measured using an automatic biochemical analyzer.
[0123] 2.4 Histopathological examination
[0124] After the experiment, the heart, liver, spleen, lung and kidney pathological materials of chickens in each group were taken, weighed, and subjected to tissue pathological section examination. The samples were fixed with 10% neutral formalin solution, embedded in paraffin, sectioned, and observed under an ordinary microscope after HE staining.
[0125] 3. Test results
[0126] 3.1 Clinical manifestations
[0127] Through observations of the feeding, spirit, breathing, drinking water, and feces of the experimental chickens, it was found that after medication, the experimental chickens in each group had a good appetite, a good mental state, no abnormal changes in feces morphology, and no deaths.
[0128] 3.2 Effects of different dosing doses on chick weight
[0129] The body weight of the chicks in each group was measured before administration and on the first day after drug withdrawal. The results are shown in Table 8.
[0130] Table 8 Effect of Example 1 on Chicken Body Weight
[0131]
[0132] As shown in Table 8, before administration and on the first day after drug withdrawal, there was no significant difference in the weight gain of chickens in the 1, 3, and 5 dose groups during the administration period, and it was slightly decreased compared with the blank control group.
[0133] 3.3 Effects of different dosing doses on chick body temperature
[0134] The body temperature of the chicks in each group was measured before administration and on the first day after drug withdrawal. The results are shown in Table 9.
[0135] Table 9 Changes in body temperature of chicken
[0136]
[0137] As shown in Table 9, before administration and on the first day after drug withdrawal, the body temperature of chickens in the 1, 3, and 5 dose groups had no significant difference compared with the blank control group (P>0.05), indicating that different dose groups had no adverse effects on the body temperature of chickens.
[0138] 3.4 Effects of different dosing doses on routine blood parameters in chickens
[0139] Before administration and on the first day after drug withdrawal, routine blood test of chicks in each group was performed. The results are shown in Tables 10 and 11.
[0140] Table 10 Routine indicators of chicken blood before administration
[0141]
[0142] Table 11 Changes of routine blood indicators of chickens on the first day after drug withdrawal
[0143]
[0144] As shown in Table 10 and Table 11, before administration and on the first day after drug withdrawal, the RBC, HGB, WBC, lymphocyte percentage (Ly), neutrophil percentage (GNR), and monocyte percentage (Mn) of the chickens in the 1, 3, and 5 dose groups were not significantly different from those in the blank control group (P>0.05). This indicates that different dose groups will not cause abnormalities in the routine blood indicators of chickens.
[0145] 3.5 Effects of different dosing doses on chicken blood biochemical parameters
[0146] Blood biochemical indexes of chicks in each group were tested before administration and on the first day after drug withdrawal. The results are shown in Tables 12 and 13.
[0147] Table 12 Blood biochemical parameters of chickens before administration
[0148]
[0149] Table 13 Changes in blood biochemical parameters of chickens on the first day after drug withdrawal
[0150]
[0151] As shown in Table 12 and Table 13, before administration and on the first day after drug withdrawal, the ALT, AST, TP, ALB, UA, Crea, TBil, and Glu of the chickens in the 1, 3, and 5 dose groups were not significantly different from those in the blank control group (P>0.05). This indicates that different dose groups will not cause abnormal blood biochemical indicators in chickens.
[0152] 3.6 Effects of different dosing doses on organ indexes
[0153] The organ indexes of the chicks in each group were tested before administration and on the first day after drug withdrawal. The results are shown in Table 14.
[0154] Table 14 Changes in chicken organ indexes on the first day after drug withdrawal
[0155]
[0156] Note: Index = organ weight mg / chicken individual weight g
[0157] As shown in Table 14, the organ indexes of the heart, liver, spleen and kidney of the chickens in the 1, 3 and 5 dose groups on the first day after drug withdrawal were not significantly different from those in the blank control group (P>0.05). This indicates that different dose groups have no significant effect on the growth of chicken organs.
[0158] 3.7 Effects of different dosing doses on pathological histology of important organs in chickens
[0159] The chickens were autopsied and observed with the naked eye. No obvious pathological changes were found in the internal organs. No obvious abnormal changes were found in the tissue morphology and color. The specific results are shown in Figure 1 . Histopathological section examination showed that no obvious pathological changes were found in the heart, liver, spleen, lung and kidney of the chickens in each dose group. The myocardial fibers were densely arranged and interconnected into a network; the central vein of the liver was obvious, and the hepatocytes were arranged radially or in rows with the central vein as the axis, with irregular sinusoids; the spleen cords and splenic sinuses were arranged alternately, the central artery was obvious, and a large number of lymphocytes and nucleated red blood cells were also visible; there were a large number of alveoli of varying sizes in the lung tissue, and the alveolar septa contained abundant capillaries; the renal tubules and collecting ducts in the kidney tissue were obvious. This shows that different dose groups will not cause pathological damage to the chicken's solid organs.
[0160] This test used 1, 3, and 5 times the recommended dose of Example 1 for drinking water administration for 5 consecutive days. During the administration period, no clinical adverse reactions occurred in the test groups during the administration period and the drug withdrawal observation period; the weight gain of the test chickens in each dosage group was not significantly different from that of the blank control group, indicating that Example 1 had no adverse effect on the weight of the chickens; the blood biochemical indicators of each dosage group were not significantly different from those of the blank control group, and the values were all within the normal range; no chickens in the test group died during the test. This shows that when Example 1 is used within the recommended dose, it has no adverse effects on the clinical symptoms, blood routine, and blood biochemistry of chickens, and no clinical adverse reactions occur. This product is safe for clinical use.
[0161] This prescription has undergone effectiveness tests and safety tests, proving that this product is safe and effective.
[0162] In summary, the above are only preferred embodiments of the present invention, and are not intended to limit the present invention in other forms. Any technician familiar with the profession may use the above technical content as inspiration to make changes or modifications. This is an equivalent embodiment of equivalent changes. However, any simple modification, equivalent changes and modifications made to the above embodiments based on the technical essence of the present invention without departing from the technical concept of the present invention still fall within the scope of protection of the claims of the present invention.
Claims
1. A Chinese medicine composition for preventing and treating poultry adenomyotic gastritis, It is characterized in that It is mainly made of the following raw materials in parts by weight: 15-30 parts of guava leaves, 15-30 parts of red magnolia, 10-20 parts of taro, 10-20 parts of galangal, 5-20 parts of cinnamomum cassia, 5-20 parts of willow, 5-10 parts of conch shell and 3-6 parts of EGF. Except for EGF, the raw materials are Chinese medicinal materials or Chinese medicinal extracts equivalent to the amount of the above-mentioned Chinese medicinal materials.
2. The drug according to claim 1, It is characterized in that The invention is prepared from the following raw materials in parts by weight: 30 parts of guava leaves, 20 parts of red magnolia, 10 parts of taro, 10 parts of galangal, 10 parts of cinnamomum villosum, 10 parts of willow bark, 10 parts of conch shell and 5 parts of EGF.
3. A method for preparing the Chinese medicine composition according to claim 1 or 2, It is characterized in that Guava leaves, galangal and cinnamon are mixed and then subjected to alcohol extraction to obtain crude extracts of guava leaves, galangal and cinnamon; the guava leaves, galangal and cinnamon residues after alcohol extraction are mixed with red magnolia, taro, willow of matsudana and conch shells, and then solvent is added for extraction, and the mixture is filtered to collect the filtrate; the filtrate is evenly mixed with the crude extracts of guava leaves, galangal and cinnamon, concentrated, and then EGF is added and mixed to obtain a traditional Chinese medicine composition.
4. The preparation method according to claim 3, It is characterized in that When guava leaves, kaempferia galanga and cinnamomea are subjected to alcohol extraction, the mass ratio of the total mass of guava leaves, kaempferia galanga and cinnamomea to the ethanol solution is 1:(10-15).
5. The preparation method according to claim 3, It is characterized in that The filtrate and the crude extract are combined and concentrated to 1 to 2 times the weight of the drug material, and then EGF is added and mixed.
6. The preparation method according to claim 3, It is characterized in that The solvent is water or ethanol solution, and the extraction method is reflux extraction.
7. Use of the Chinese medicine composition according to claim 1 or 2 in the preparation of a medicament for treating poultry adenomyotic gastritis.
8. A drug for preventing and treating poultry adenomyotic gastritis, It is characterized in that The medicine is prepared from the Chinese medicine composition according to claim 1 or 2 and pharmaceutically acceptable excipients.
9. The drug according to claim 8, It is characterized in that The drug is in oral dosage form.
10. The drug according to claim 9, It is characterized in that The medicine is in the form of oral liquid, granules or extract powder.
